AIDS, a chronic disease caused by the HIV virus, severely damages the immune system, impairing the body’s ability to fight infections and diseases. Due to its seriousness and potential for fatal outcomes, a definitive medical diagnosis involving tests and imaging is crucial.
In response to the challenges faced by individuals with multi-drug resistant HIV infections, the US Food and Drug Administration (FDA) has recently approved “twice-yearly injections” and pills. Among these, Sunlenca (lenacapavir), an injectable medication, is being celebrated by specialists as a groundbreaking advancement in HIV treatment. This development brings new hope to those living with HIV, offering a potentially transformative approach to managing the disease.
However, recent reports about the high cost of these injectable medications are causing concern among HIV-positive individuals. The financial burden of such treatments is a significant issue, and many are struggling with the prospect of expensive care. In Kenya, there is limited awareness about these recent developments in the United States.
We invite you to share your thoughts on this situation. As a leading platform in the country, we value your input and are eager to hear your perspectives on how these advancements and associated costs are affecting those living with HIV.
